2. Search Result
Search Result
Results for "

Osteoclastogenesis

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

27

Natural
Products

3

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2119
    Sciadopitysin
    1 Publications Verification

    		 TNF Receptor NF-κB Inflammation/Immunology
    Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .
    Sciadopitysin
  • HY-110318
    VUF11207 fumarate
    2 Publications Verification

    		 CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-120140
    Ganoderic acid DM
    1 Publications Verification

    		 Apoptosis PI3K Metabolic Disease Inflammation/Immunology Cancer
    Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis .
    Ganoderic acid DM
  • HY-111266
    Halenaquinone

    		PI3K Apoptosis Inflammation/Immunology Cancer
    Halenaquinone is a phosphatidylinositol 3-kinase inhibitor and can be isolated from the marine sponge Petrosia alfiani. Halenaquinone inhibits RANKL-induced osteoclastogenesis, and induces cell apoptosis in PC12 cells .
    Halenaquinone
  • HY-N12555
    6,6′-Didemethyl-7-methyl dragonbloodin A2

    		Others Others
    6,6′-Didemethyl-7-methyl dragonbloodin A2 is isolated from the dragon’s blood of Daemonorops draco fruits and is a osteoclastogenesis inhibitor with IC50 value of 36.8 μM[1].
    6,6′-Didemethyl-7-methyl dragonbloodin A2
  • HY-N10838
    Ajudecunoid A

    		Others Others
    Ajudecunoid A is nature product that could be isolated from Ajuga decumbens. Ajudecunoid A inhibits RANKL-Induced osteoclastogenesis .
    Ajudecunoid A
  • HY-N3188
    Niloticin

    		Akt NF-κB Infection
    Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways .
    Niloticin
  • HY-155960
    SH491

    		Others Inflammation/Immunology
    SH491 (Compound 33) is an antiosteoporosis agent. SH491 inhibits RANKL-induced osteoclast differentiation on bone-marrow-derived monocytes (BMMs) (IC50: 11.8 nM). SH491 inhibits the expression of osteoclastogenesis-related marker genes (TRAP, CTSK, MMP-9, and ATPase v0d2) and proteins (TRAP, CTSK, MMP-9) .
    SH491
  • HY-162847
    S24–14

    		Others Metabolic Disease
    S24–14 is a potent antiosteoporosis agent. S24–14 inhibits osteoclastogenesis with an IC50 value of 0.40 µM. S24–14 induces osteoblast differentiation. S24–14 suppresses bone loss .
    S24–14
  • HY-N2119R
    Sciadopitysin (Standard)

    		TNF Receptor NF-κB Inflammation/Immunology
    Sciadopitysin (Standard) is the analytical standard of Sciadopitysin. This product is intended for research and analytical applications. Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .
    Sciadopitysin (Standard)
  • HY-149472
    Anti-osteoporosis agent-4

    		NF-κB PI3K Inflammation/Immunology
    Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .
    Anti-osteoporosis agent-4
  • HY-N11775
    Eudebeiolide B

    Plebeiolide D

    		 NF-κB Akt Nuclear Factor of activated T Cells (NFAT) Phosphatase Metabolic Disease
    Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating RANKL-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research .
    Eudebeiolide B
  • HY-149852
    Anti-osteoporosis agent-3

    		Others Inflammation/Immunology
    Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
    Anti-osteoporosis agent-3
  • HY-125911
    Gossypin

    		NF-κB Cardiovascular Disease Inflammation/Immunology Cancer
    Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro .
    Gossypin
  • HY-125911R
    Gossypin (Standard)

    		NF-κB Cardiovascular Disease Inflammation/Immunology Cancer
    Gossypin (Standard) is the analytical standard of Gossypin. This product is intended for research and analytical applications. Gossypin is a flavone isolated from?Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro .
    Gossypin (Standard)
  • HY-N9736
    6,4'-Dihydroxy-7-methoxyflavanone

    		Calcineurin Infection Neurological Disease Inflammation/Immunology
    6,4'-Dihydroxy-7-methoxyflavanone, a flavonoid, is a nature product that could be isolated from Heartwood Dalbergia odorifera. 6,4'-Dihydroxy-7-methoxyflavanone inhibits receptor activators of nuclear factor kappa-B ligand (RANKL) induced osteoclastogenesis. 6,4'-Dihydroxy-7-methoxyflavanone has antioxidant, anti-inflammatory and neuroprotective effects. 6,4'-Dihydroxy-7-methoxyflavanone can be used in research of osteoporosis .
    6,4'-Dihydroxy-7-methoxyflavanone
  • HY-12212
    Omaveloxolone
    Maximum Cited Publications
    18 Publications Verification

    RTA 408

    		 Keap1-Nrf2 STING Apoptosis Inflammation/Immunology Cancer
    Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
    Omaveloxolone
  • HY-N12740
    Napyradiomycin B4

    		MEK ERK Others
    Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis .
    Napyradiomycin B4
  • HY-N10076
    Ganomycin I

    		HMG-CoA Reductase (HMGCR) Glucosidase HIV Protease Infection Metabolic Disease
    Ganomycin I is a dual inhibitor of α-Glucosidase and HMG-CoA reductase. Ganomycin I can also inhibits HIV protease. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects .
    Ganomycin I
  • HY-153675
    BCPA

    		PIN1 Metabolic Disease
    BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research .
    BCPA
  • HY-110063
    4-IPP
    3 Publications Verification

    4-Iodo-6-phenylpyrimidine

    		 Macrophage migration inhibitory factor (MIF) Metabolic Disease
    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF) .
    4-IPP
  • HY-161848
    TCP-MP-CA

    		Histone Demethylase Cancer
    TCP-MP-CA (compound 11a) is an inhibitor of LSD1 demethylation enzymatic via binding to LSD1/CoREST complex. TCP-MP-CA exhibits an inhibitory effect on osteoclastogenesis, with an IC50 value of 0.14 µM .
    TCP-MP-CA
  • HY-155342
    A3373

    		Phospholipase Inflammation/Immunology
    A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis .
    A3373
  • HY-N13219
    Angelica Extract

    		Others Metabolic Disease
    Angelica Extract is an angelica extract, and its components include: Ligustilide. Angelica Extract can effectively inhibit the differentiation of osteoclasts, regulate osteoclastogenesis and/or bone loss. Angelica Extract has the potential to be used in the study of various bone diseases caused by excessive bone resorption. .
    Angelica Extract
  • HY-158098
    FGFR1 inhibitor-11

    		FGFR Metabolic Disease
    FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity .
    FGFR1 inhibitor-11
  • HY-158311
    Anti-osteoporosis agent-8

    		RANKL/RANK p38 MAPK NF-κB Endocrinology
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .
    Anti-osteoporosis agent-8
  • HY-118482
    Sauristolactam

    Saurolactam

    		 Others Neurological Disease
    Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells . Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation .
    Sauristolactam
  • HY-N12604
    Penicisteck acid F

    		NF-κB Others
    Penicisteck acid F (Compound 2) is a Marine derived tanzanic acid derivative that is a NF-κB inhibitor. Penicisteck acid F inhibits osteoclast expression by decreasing RANKL-induced IκBα degradation, NF-κB p65 nuclear translocation, NFATc1 activation and nuclear translocation, and related mRNA expression. Penicisteck acid F can be used in osteoporosis research .
    Penicisteck acid F
  • HY-130237
    Cinnamtannin B-1

    		Reactive Oxygen Species Metabolic Disease Cancer
    Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
    Cinnamtannin B-1
  • HY-161869
    LSD1-IN-32

    		Histone Methyltransferase Metabolic Disease
    LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC50 value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis .
    LSD1-IN-32
  • HY-N6052
    (+)-Medicarpin

    		Estrogen Receptor/ERR Cancer
    (+)-Medicarpin, a pterocarpan, is a type of isoflavonoid isolated from several medicinal plant species with various biological effects, including Sophora japonica, Zollernia paraensis and Platymiscium yucatamun, Machaerium aristulatum, Platymiscium floribundum, and so on. (+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action .
    (+)-Medicarpin
  • HY-N0231
    Bavachalcone
    2 Publications Verification

    Broussochalcone B

    		 Bacterial Antibiotic NF-κB PERK Akt Autophagy Apoptosis Infection Neurological Disease Inflammation/Immunology Cancer
    Bavachalcone is a potent inducer of apoptosis. Bavachalcone exerts anticancer activity by promoting autophagy and apoptosis in HepG2 cells. Bavachalcone acts as an anti-neuroinflammatory and antidepressant through the NF-κB pathway. Bavachalcone inhibits osteoclasts by interfering with ERK and Akt signaling pathways and the expression of c-Fos and NFATc1. Bavachalcone exhibits a significant inhibitory effect on baculovirus-expressed BACE-1 in vitro .
    Bavachalcone
  • HY-124958
    NDMC101

    		NF-κB Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al .
    NDMC101
  • HY-N6973R
    Boldine (Standard)

    		RANKL/RANK Inflammation/Immunology
    Boldine (Standard) is the analytical standard of Boldine. This product is intended for research and analytical applications. Boldine is an aporphine isoquinoline alkaloid extracted from the root of Litsea cubeba and also possesses these properties, including antioxidant, anti-inflammatory and cytoprotective effects. Boldine suppresses osteoclastogenesis, improves bone destruction by down-regulating the OPG/RANKL/RANK signal pathway and may be a potential therapeutic agent for rheumatoid arthritis .
    Boldine (Standard)
  • HY-162280
    PROTAC BTK Degrader-9

    		PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk Cancer
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .
    PROTAC BTK Degrader-9
  • HY-W438351
    1,3-Dibenzyl-5-fluorouracil

    		RANKL/RANK Metabolic Disease
    1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases .
    1,3-Dibenzyl-5-fluorouracil
  • HY-N1746
    (2S)-2'-Methoxykurarinone

    2'-O-Methylkurarinone

    		 RANKL/RANK Metabolic Disease Inflammation/Immunology Cancer
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .
    (2S)-2'-Methoxykurarinone
  • HY-130237R
    Cinnamtannin B-1 (Standard)

    		Reactive Oxygen Species Metabolic Disease Cancer
    Cinnamtannin B-1 (Standard) is the analytical standard of Cinnamtannin B-1. This product is intended for research and analytical applications. Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
    Cinnamtannin B-1 (Standard)
  • HY-N12561
    Pestanoid A

    		ERK p38 MAPK JNK Others
    Pestanoid A is a rearranged pimarane diterpenoid osteoclastogenesis inhibitor with an IC50 of 4.2 μM. Pestanoid A can be isolated from the marine mesophotic zone chalinidae sponge-associated fungus, Pestalotiopsis sp. NBUF145. Pestanoid A inhibits the receptor activator of NF-kB ligand-induced MAPK and NF-κB signaling by suppressing the phosphorylation of ERK1/2-JNK1/2-p38 MAPKs and NF-κB nuclear translocation. Pestanoid A can be used for the study of osteoporosis .
    Pestanoid A
  • HY-145491
    Resolvin D5

    		ERK NF-κB Inflammation/Immunology
    Resolvin D5 is a prolytic mediator (SPM) with anti-inflammatory activity derived from oxidized lipids DHA. Resolvin D5 inhibits Th17 cell differentiation and promotes regulatory T cell differentiation, and inhibits CD4+ T cell proliferation. Resolvin D5 attenuates osteoclast differentiation and interferes with osteoclastogenesis. Resolvin D5 also regulates ERK phosphorylation and nuclear translocation of NF-kappaB. Resolvin D5 could be used in rheumatoid arthritis research .
    Resolvin D5
  • HY-13777C
    Zoledronate disodium

    CGP 42446 disodium; CGP42446A disodium; ZOL 446 disodium

    		 Others Cancer
    Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone turnover and stabilizing the bone matrix. Zoledronate disodium has demonstrated notable effectiveness in managing Paget's disease of bone by suppressing metabolic activity and alleviating bone pain. Zoledronate disodium is being investigated in the ongoing ZiPP trial for its potential to prevent disease progression in patients with Paget's disease. Zoledronate disodium also exhibits diverse anti-tumor effects in osteosarcoma, further highlighting its multifunctional therapeutic applications.
    Zoledronate disodium
  • HY-N0755
    Rhoifolin

    		Insulin Receptor GLUT NF-κB p38 MAPK Autophagy Metabolic Disease Endocrinology Cancer
    Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .
    Rhoifolin
  • HY-147369
    NFATc1-IN-1
    1 Publications Verification

    		 Nuclear Factor of activated T Cells (NFAT) Others
    NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .
    NFATc1-IN-1
  • HY-N0507
    Rosavin

    		TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .
    Rosavin
  • HY-N0755R
    Rhoifolin (Standard)

    		Insulin Receptor GLUT NF-κB p38 MAPK Autophagy Metabolic Disease Endocrinology Cancer
    Rhoifolin (Standard) is the analytical standard of Rhoifolin. This product is intended for research and analytical applications. Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .
    Rhoifolin (Standard)
  • HY-N0507R
    Rosavin (Standard)

    		TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    Rosavin (Standard) is the analytical standard of Rosavin. This product is intended for research and analytical applications. Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .
    Rosavin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: